Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
despite the lack of progress in achieving markedly higher solubility
1219707-39-7
C[C@@](O)([C@H](CC([O-])=O)C([O-])=O)C([O-])=O
which treats illnesses associated with rapid heartbeats such as atrial and ventricular arrhythmias
Smiles: CC[C@@H](C1=C(O)C[C@@](CCC)(CCC2C=CC=CC=2)OC1=O)C1=CC(=CC=C1)NS(=O)(=O)C1=CC=C(C=N1)C(F)(F)F
Regorafenib Catalog No.:M10913-10 despite the lack of progressRegorafenib, also known as BAY 73 4506 ; is a n orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. Regorafenib demonstrated to increase the overall survival of patients with metastatic
US$ 26.47
US$ 159.00
US$ 30.00
US$ 19.86
US$ 24.76
US$ 30.00
US$ 30.00
US$ 26.70
US$ 17.06
US$ 22.87
US$ 70.53
US$ 24.76
US$ 79.95
US$ 29.30